title: Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study.
abstract: Sixty postmenopausal women with advanced breast cancer entered a phase II study, evaluating idarubicin (IDA) in a weekly schedule. Starting dose was 22.5 mg/m2, and median age was 65 years. Five patients were considered ineligible and the response rate among 55 eligible patients was 33%. Median time to treatment failure was 19 weeks and median duration of tumor regression for 18 responding patients was 40 weeks. Hematologic toxicity was moderate and non-hematologic toxicity was mild. The study shows that IDA, administered orally in a weekly schedule, has pharmacodynamic properties comparable to IDA in a 3-weekly schedule and to doxorubicin in the treatment of advanced breast cancer.
authors.affiliation: Department of Oncology ONA, Finsen Institute, Copenhagen, Denmark.
authors.forename: L
authors.initials: L
authors.lastname: Bastholt
authors.forename: M
authors.initials: M
authors.lastname: Dalmark
authors.forename: A
authors.initials: A
authors.lastname: Jakobsen
authors.forename: C C
authors.initials: CC
authors.lastname: Gadeberg
authors.forename: E
authors.initials: E
authors.lastname: Sandberg
authors.forename: H T
authors.initials: HT
authors.lastname: Mouridsen
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D008593:Menopause; D008875:Middle Aged
chemical_list: D015255:Idarubicin